drugset / Trial / NCT04342793

A Study to Evaluate the Efficacy and Safety of ALS-L1023 in Subjects With NASH

NCT04342793

Phase 2 Completed 60 enrolled AngioLab, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The main objective of this study is to evaluate safety and efficacy of ALS-L1023 in patients with Non-alcoholic steatohepatitis

Timeline

Start
2019-12-04
Primary completion
2021-05-11
Completion
2021-05-11

Drugs

EvaluationDrugModalityDoseRoute
Subject ALS-L1023 Unknown 1200 mg
Subject ALS-L1023 Unknown 1800 mg